For example, GSK2256098, classified as a FAK-FERM structural domain inhibitor by inhibiting autophosphorylation at the FAK Tyr397 site, has demonstrated good tolerability and efficacy in patients with recurrent merlin-negative mesothelioma and recurrent/progressive NF2-mutant meningiomas (ClinicalTrials.gov: NCT01138033, NCT02523014) [507–509]. Here, NF2 is linked to mesothelioma.